Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06601725
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-09-16
Brief Title:
Clusterin Level and Polycystic Ovary Syndrome
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clusterin Level Determination and Its Association With Metabolic Syndrome in Patients With Polycystic Ovary Syndrome
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Clusterin a protein involved in metabolic syndrome insulin resistance and metabolic disorders associated with inflammation and oxidative stress such as atherosclerosis Alzheimers and some malignancies has elevated levels in metabolic syndrome PCOS and the combination of these two groups Clusterin could be used as an inflammatory marker to predict PCOS and metabolic syndrome
Detailed Description:
The study included 118 women diagnosed with PCOS according to the Rotterdam criteria and 62 age-matched healthy women without cardiovascular risk factors The patients diagnosed with PCOS were also classified into phenotypes No interventional examination was requested for patients A B C and D except for hormonal tests and blood collection for Human Clusterin The demographic and clinical characteristics of all patients were compared with the primary outcome being blood Clusterin levels The secondary outcomes are blood Clusterin levels in women with and without metabolic syndrome in addition to PCOS the relationship between PCOS phenotypes and Clusterin levels and the relationship between Clusterin levels and clinical and laboratory parameters
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None